Immunome IMNM
NASDAQ IMNM
$18.08 +0.16 (+0.89%)
As of: Oct 21, 2026 · 2:09 PM EDT

Immunome (IMNM) EBIT Margin (2020 - 2025)

Updated

Immunome's EBIT Margin came in at -3228.83% for FY2025, up 153.54 percentage points from -3382.37% in FY2024.

Analysis

Immunome (IMNM) EBIT Margin (2020 - 2025) Analysis & Trends

  • Per Business Quant, earlier years put EBIT Margin at -3382.37% in FY2024 (-2601.02 pp) and -781.35% in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Eli Lilly 1,133.90 Bn 1,102.48 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 616.46 Bn 534.99 Bn 17.26 Bn 28.21%
3 AbbVie 501.26 Bn 474.37 Bn 12.70 Bn 37.86%
4 Merck 367.00 Bn 321.38 Bn 12.21 Bn -3.52%
5 Novartis Ag 297.91 Bn 261.90 Bn 11.24 Bn 32.97%
6 Astrazeneca 261.33 Bn 235.02 Bn 12.86 Bn 20.57%
7 Amgen 235.82 Bn 191.22 Bn 7.24 Bn 34.95%
8 Gilead Sciences 190.63 Bn 164.82 Bn 6.22 Bn -133.21%
9 Pfizer 169.35 Bn 115.99 Bn 10.94 Bn 28.37%
10 Immunome 2.05 Bn 21.41 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -1,157.61%
Mar 31, 2025 -1,525.50%
Dec 31, 2024 -3,030.31%
Sep 30, 2024 -1,736.15%
Jun 30, 2024 -1,692.43%
Mar 31, 2024 -12,857.05%
Dec 31, 2023 -2,473.94%
Sep 30, 2023 -129.96%
Jun 30, 2023 -135.42%
Mar 31, 2023 -189.13%
Dec 31, 2022 -778,700.00%
Sep 30, 2022 -853,400.00%
Jun 30, 2022 -446,300.00%
Mar 31, 2022 -1,165,400.00%
Jun 30, 2020 -54,300.00%
API Access

Immunome EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=IMNM&period=max&api_key=YOUR_API_KEY